C-Terminal Residue Optimization and Fragment Merging: Discovery of a Potent Peptide-Hybrid Inhibitor of Dengue Protease

Dengue virus protease is a promising target for the development of antiviral drugs. We describe here a two-step rational optimization that led to the discovery of the potent inhibitor <bold>35</bold> with nanomolar binding affinity at dengue protease serotype 2 (IC50 = 0.6 mu M, K-i = 0.4 mu M). First, a large number of natural and non-natural amino acids were screened at the C-terminal position of the previously reported, canonical peptide sequence (Cap-Arg-Lys-Nle-NH2). Compared to the reference compound <bold>1</bold> (Bz-Arg-Lys-Nle-NH2, IC50 = 13.3 mu M), a 4-fold higher inhibitory potential was observed with the incorporation of a C-terminal phenylglycine (compound <bold>9</bold>, IC50 = 3.3 mu M). Second, we applied fragment merging of <bold>9</bold> with the previously reported thiazolidinedione peptide hybrid <bold>33</bold> (IC50 = 2.5 mu M). This approach led to the fusion of two inhibitor-fragments with micromolar affinity into a 20-fold more potent, competitive inhibitor of dengue protease.